HomeCompareATNX vs CHD

ATNX vs CHD: Dividend Comparison 2026

ATNX yields 984.74% · CHD yields 1.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATNX wins by $16481957.01M in total portfolio value
10 years
ATNX
ATNX
● Live price
984.74%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$16481957.04M
Annual income
$13,737,663,418,719.40
Full ATNX calculator →
CHD
CHD
● Live price
1.28%
Share price
$93.32
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,302.64
Full CHD calculator →

Portfolio growth — ATNX vs CHD

📍 ATNX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATNXCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATNX + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATNX pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATNX
Annual income on $10K today (after 15% tax)
$83,702.61/yr
After 10yr DRIP, annual income (after tax)
$11,677,013,905,911.49/yr
CHD
Annual income on $10K today (after 15% tax)
$108.62/yr
After 10yr DRIP, annual income (after tax)
$1,107.24/yr
At 15% tax rate, ATNX beats the other by $11,677,013,904,804.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATNX + CHD for your $10,000?

ATNX: 50%CHD: 50%
100% CHD50/50100% ATNX
Portfolio after 10yr
$8240978.53M
Annual income
$6,868,831,710,011.02/yr
Blended yield
83.35%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

ATNX
Analyst Ratings
5
Buy
5
Hold
Consensus: Buy
Altman Z
-7.5
Piotroski
4/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+5.4% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATNX buys
0
CHD buys
11
PoliticianChamberTickerTypeAmountDate
Richard W. Allen🏢 House$CHD▼ Sell$15,001 - $50,0002025-10-10
Ro Khanna🏢 House$CHD▲ Buy$1,001 - $15,0002025-09-29
Lisa McClain🏢 House$CHD▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CHD▲ Buy$1,001 - $15,0002025-08-04
Ro Khanna🏢 House$CHD▲ Buy$1,000 - $15,0002025-08-04
Lisa McClain🏢 House$CHD▼ Sell$1,001 - $15,0002025-06-24
Lisa McClain🏢 House$CHD▲ Buy$1,001 - $15,0002025-06-17
Jonathan Jackson🏢 House$CHD▼ Sell$15,001 - $50,0002025-05-14
Jonathan Jackson🏢 House$CHD▼ Sell$1,001 - $15,0002025-05-05
Jonathan Jackson🏢 House$CHD▲ Buy$1,001 - $15,0002025-04-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATNXCHD
Forward yield984.74%1.28%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$16481957.04M$26.4K
Annual income after 10y$13,737,663,418,719.40$1,302.64
Total dividends collected$16271814.37M$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ATNX vs CHD ($10,000, DRIP)

YearATNX PortfolioATNX Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$109,174$98,473.66$10,857$157.30+$98.3KATNX
2$1,121,557$1,004,741.08$11,814$196.49+$1.11MATNX
3$10,846,656$9,646,590.10$12,887$245.97+$10.83MATNX
4$98,795,506$87,189,583.88$14,097$308.68+$98.78MATNX
5$847,913,243$742,202,051.48$15,473$388.49+$847.90MATNX
6$6,860,496,352$5,953,229,181.85$17,046$490.55+$6860.48MATNX
7$52,357,357,343$45,016,626,246.62$18,861$621.76+$52357.34MATNX
8$377,100,961,928$321,078,589,571.04$20,973$791.47+$377100.94MATNX
9$2,564,760,394,425$2,161,262,365,161.88$23,454$1,012.51+$2564760.37MATNX
10$16,481,957,040,754$13,737,663,418,719.40$26,398$1,302.64+$16481957.01MATNX

ATNX vs CHD: Complete Analysis 2026

ATNXStock

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

Full ATNX Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this ATNX vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATNX vs SCHDATNX vs JEPIATNX vs OATNX vs KOATNX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.